FDA Updates Plavix Labeling to Warn Against Co-Administration with Other CYP2C19 Inhibitors | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has updated the labeling for Plavix to warn consumers and doctors about the concomitant use of the anti-platelet agent and CYP2C19-inhibiting agents, such as the proton pump inhibitor Prilosec and others.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.